Cancer is among the leading causes of death worldwide, with 9.7 million people losing their lives to it in 2022. By 2040, the number of cancer-related deaths is projected to reach 15.3 million, according to the National Cancer Institute.Â
Cancer profoundly impacts not just American society but communities worldwide. With numerous types, from ovarian to prostate cancer, prioritizing proactive health measures is more important than ever.
So, if there was a test that could spot the early symptoms and internal abnormalities before the disease progresses, why wouldn’t we take it?Â
Ovarian cancer is often called a silent disease, which is only half true. It does produce symptoms, but they are easy to mistake for something ordinary. Knowing what those early signs of ovarian cancer look like is genuinely the most useful thing on this page, so that is where we will spend most of it.
Keep reading to find the answers.Â
What is Ovarian Cancer?
In a general sense, cancer begins when cells begin to grow out of control in any area of the body. According to the American Cancer Society, ovarian cancer is one of the leading causes of cancer deaths among women, with a projected risk of one in 87 women receiving the diagnosis during her lifetime.Â
What Are the Ovaries?Â
Ovaries are the female reproductive glands that produce eggs, or ova, and the female hormones estrogen and progesterone. During the reproductive process, the eggs travel from the ovaries into the fallopian tubes, eventually settling in the uterus, where the eggs develop into a fetus.Â
While ovarian cancer was originally believed to begin in the ovaries, new studies suggest that the cancer can start in the far end of the fallopian tubes.Â
While some of these tumors can end up being non-cancerous, others present the potential of being malignant or borderline.Â
Early Symptoms of Ovarian CancerÂ
One of the more challenging aspects of identifying the early stages of ovarian cancer lies in its symptoms.Â
When ovarian cancer starts to develop, symptoms may not be present, or if they do, they are easily attributed to other common conditions like indigestion or cramps.
Some of the most common symptoms of ovarian cancer include bloating, diarrhea, and abdominal pain. Other symptoms and signs of ovarian cancer may include the following:Â
- Immediate feelings of fullness when eatingÂ
- Weight lossÂ
- Discomfort in the pelvic areaÂ
- FatigueÂ
- Back painÂ
- Changes in bowel habitsÂ
- Increased need to urinateÂ
The American Cancer Society reports that only about 20% of ovarian cancers are found at an early stage, making ovarian cancer screening and testing all the more critical. While the ‘big four’ cancers—breast, lung, prostate, and colorectal—account for almost half of all new cancer cases in the United States, early detection remains key for improving outcomes in all types of cancer.
How Is Ovarian Cancer Actually Detected?
Here we have to be straight with you, because this is exactly the point where a clinic like ours is tempted to overreach.
There is no reliable screening test for ovarian cancer, and that is not a gap waiting for a scan to fill. The U.S. Preventive Services Task Force actively recommends against screening for ovarian cancer in women at average risk who have no symptoms, a Grade D recommendation. The reason is not that nobody has tried. Large trials found that screening did not reduce deaths from ovarian cancer, while false positives led to women having surgery, including removal of ovaries, for what turned out to be benign.
So we are not going to tell you a whole-body MRI screens for ovarian cancer. It does not, and no imaging test has been shown to reduce ovarian cancer deaths in the general population.
What actually happens when ovarian cancer is suspected: a pelvic examination, a transvaginal ultrasound as the first-line imaging test, and a CA-125 blood test read in context, since CA-125 also rises with endometriosis, fibroids, infection, menstruation and pregnancy. If a mass stays indeterminate after ultrasound, a dedicated pelvic MRI with contrast is the problem-solving study. A diagnosis is ultimately confirmed by a pathologist.
Stage Really Does Matter
According to SEER data from the National Cancer Institute, 5-year relative survival for ovarian cancer is 91.9 percent when it is still confined to the ovary. That falls to 71.5 percent once it has reached regional lymph nodes and 31.4 percent once it has spread to distant sites. Across all stages it is 50.9 percent.
Only about 19 percent of cases are caught at that earliest stage, while 55 percent are not found until the cancer has already spread. That is why symptom awareness matters so much: for now, noticing the pattern and acting on it is the earliest realistic detection route most women have.
You will sometimes see ovarian cancer survival quoted as around 11 percent. That figure is wrong and we would rather correct it than repeat it.
If You Are at Higher Risk
A family history of ovarian, breast or colorectal cancer can raise your risk, and so can an inherited variant such as BRCA1 or BRCA2 or Lynch syndrome. If that describes you, the right step is not a screening scan. It is a conversation with your doctor about genetic counselling and testing, because women with a confirmed high-risk variant are managed by a specialist team with options that genuinely change outcomes, including risk-reducing surgery.
Where We Do Fit
Our whole-body scan gives a broad structural look at 13 organ systems with no radiation and no contrast dye. It can find things incidentally, including an ovarian cyst nobody was looking for, and the right next step for such a finding is a dedicated pelvic ultrasound. Most turn out to be ordinary and benign.
If you have persistent bloating, pelvic pain, feeling full quickly or urinary changes lasting more than a few weeks, please see your doctor rather than booking a scan. If you want a broad structural baseline while you are well, schedule an appointment or talk to our team first.
This article is for general education and is not medical advice.
Frequently asked questions
What are the early signs of ovarian cancer?
The most common are bloating, pelvic or abdominal pain, feeling full quickly when eating, and needing to urinate more often or urgently. Others include fatigue, back pain, changes in bowel habits and unexplained weight loss. What matters is the pattern rather than any single symptom: if these are new for you, persistent, and happening most days for more than a few weeks, that is worth a doctor appointment.
Is there a screening test for ovarian cancer?
No, and this is important. The U.S. Preventive Services Task Force recommends against screening average-risk women without symptoms, a Grade D recommendation. Large trials found screening did not reduce deaths from ovarian cancer, while false positives led to women undergoing surgery for findings that turned out to be benign. No imaging test, MRI included, has been shown to reduce ovarian cancer deaths in the general population.
Does a whole-body MRI screen for ovarian cancer?
No, and we will not describe it that way. Our scan can find an ovarian cyst or mass incidentally, and the correct next step for such a finding is a dedicated pelvic ultrasound. Most turn out to be ordinary and benign. That is a genuine benefit and a genuine limit, stated together.
How is ovarian cancer diagnosed?
Through a pelvic examination, a transvaginal ultrasound as the first-line imaging test, and a CA-125 blood test read in context, since CA-125 also rises with endometriosis, fibroids, infection, menstruation and pregnancy. If a mass remains indeterminate after ultrasound, a dedicated pelvic MRI with contrast is the problem-solving study. Diagnosis is confirmed by a pathologist examining tissue.
What is the survival rate for ovarian cancer?
It depends heavily on stage. SEER data give 5-year relative survival of 91.9 percent when the cancer is confined to the ovary, 71.5 percent once it has reached regional lymph nodes, and 31.4 percent once it has spread to distant sites. Across all stages it is 50.9 percent. Only about 19 percent of cases are caught at the earliest stage. Figures around 11 percent circulate widely and are not supported by any SEER series.
